Special Issue "Ovarian Cancer Biomarkers, Diagnostic and Therapeutic Technologies"
Deadline for manuscript submissions: 30 June 2022.
School of Translational Sciences, Monash University, Victoria VIC 3800, Australia
Interests: Ovarian cancer; diagnostics; therapeutics; cancer immunity; precision medicine; theranostics; translational medicine; biobanking
Ovarian cancer remains one of the most lethal of gynaecological malignancies, characterised in most patients by recurrent, persistent disease and the rapid acquisition of chemo-resistance. Substantial molecular heterogeneity and co-existing phenotypes at diagnosis further complicate treatment choices and efficacy. New, “game-changing” therapies, applied successfully for the treatment of other solid tumour types, have proven largely ineffective against ovarian cancers. There is a clear and urgent need for improved diagnostic, prognostic and therapeutic tools, with clear translational potential, to assist in clinical management and reduce mortality from this disease.
Early diagnosis—ideally of pre-cancerous lesions, and particularly in asymptomatic women—remains a major challenge in ovarian cancer management. Equally as important, prognostic and predictive approaches are required to detect recurrence and enhance therapeutic management for patients in whom primary care is likely to fail. Combined with approaches to identify new druggable targets and therapeutic strategies—whether synergistic or stand-alone—research is poised to exert a substantial and positive impact over clinical ovarian cancer management.
This Special Issue will focus on emerging technologies with the potential to improve the diagnosis, prognostic evaluation and therapeutic management ovarian cancers.
Dr. Andrew Stephens
Dr. Maree Bilandzic
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.